Pharma: Other News To Note
Monday, December 2, 2013
• Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA granted orphan drug exclusivity for Treanda (bendamustine) through October 2015 for indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a rituximab-containing regimen.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.